Neve Yarak, Israel — November 18, 2025 — Leads & Copy —
N2OFF, Inc. (NASDAQ: NITO), a cleantech firm focused on solar energy assets, has shared an update from Dr. Alon Silberman, CEO of MitoCareX Bio Ltd., following its acquisition of MitoCareX Bio Ltd. The update includes a letter to shareholders outlining MitoCareX’s strategic direction, near-term milestones, and development plans within the precision oncology market.
In the shareholder letter, Dr. Silberman expressed enthusiasm about the progress and vision of MitoCareX Bio Ltd., a biotechnology company utilizing MITOLINE™, its proprietary algorithm for 3D modeling of mitochondrial transport proteins. This algorithm drives the company’s drug discovery process, supporting the development of novel therapies for cancers that are difficult to treat.
MITOLINE™ is designed for broader application and future licensing, creating opportunities for collaboration and value generation across the biopharmaceutical ecosystem, beyond powering MitoCareX’s internal oncology programs.
MitoCareX is advancing a precision oncology pipeline targeting a mitochondrial SLC25 transport protein involved in the metabolic reprogramming of aggressive cancers like lung and pancreatic cancer. These two lethal malignancies are projected to represent a global therapeutic market exceeding $50 billion by 2026. MitoCareX aims to design first-in-class therapeutics that disrupt cancer metabolism at its core, positioning the company within a fast-growing area of precision oncology by integrating molecular insight with advanced computational modeling.
MITOLINE™ translates biological insight into a compounding data asset, accelerating internal programs and enabling recurring revenue through external collaborations. The algorithm’s outputs, including sequence alignments and 3D comparative models of mitochondrial SLC25 transport proteins, form the foundation for high throughput in silico screening of millions of small molecules to identify drug candidates. MitoCareX has created a unified discovery platform that integrates computational 3D modeling, candidate prediction, structure-based drug design, and experimental validation.
MitoCareX has identified hit compounds with measurable biological activity, validating the predictive ability of its MITOLINE™-based modeling approach. In 2026, the company will focus on hit-to-lead medicinal chemistry optimization, pharmacokinetic profiling, and further biological validation, aiming to nominate a preclinical development candidate.
The company is also exploring strategic collaborations and potential licensing agreements to expand MITOLINE™’s applications beyond its core programs, allowing external organizations to leverage its platform while creating non-dilutive revenue opportunities for MitoCareX.
Looking beyond 2026, MitoCareX plans to prepare for IND-enabling studies and establish MITOLINE™ as a scalable discovery engine. Through licensing, data partnerships, and co-development programs, MITOLINE™ has the potential to generate recurring revenue streams and extend MitoCareX’s scientific reach into metabolic disorders and inflammatory diseases. The goal is to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into a sustained engine of innovation and value creation.
MitoCareX’s approach combines mitochondrial biology, computational modeling, and precision oncology. The company’s focus on the mitochondrial SLC25 family and the scalability of MITOLINE™ positions it within the next generation of drug discovery companies.
MitoCareX is pioneering a new therapeutic frontier aimed at transforming outcomes for patients with cancers and other metabolic disorders that currently lack effective treatments by focusing on mitochondrial transporters.
The company’s mission is to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into a sustained engine of innovation and value creation.
N2OFF is a cleantech company mainly engaged in EU based solar assets using the RTB (Ready to Build ) business model. N2OFF is currently the lead investor in four solar projects in three different EU countries, all of which were introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments for fruits and vegetables, aiming to control and prevent pathogen contamination.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
Source: N2OFF, Inc.
